Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-06-28
2011-06-28
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387300, C424S130100, C424S133100, C424S141100
Reexamination Certificate
active
07968690
ABSTRACT:
The invention concerns agonist anti-trkC antibodies, polypeptides, and polynucleotides encoding the same. The invention further concerns use of such antibodies, polypeptides and/or polynucleotides in the treatment and/or prevention of neuropathies, such as sensory neuropathies, including taxol-induced sensory neuropathy, cisplatin-induced sensory neuropathy, and pyridoxine-induced sensory neuropathy.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4485045 (1984-11-01), Regen
patent: 4544545 (1985-10-01), Ryan et al.
patent: 4676980 (1987-06-01), Segal et al.
patent: 4777127 (1988-10-01), Suni et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5047335 (1991-09-01), Paulson et al.
patent: 5219740 (1993-06-01), Miller et al.
patent: 5225539 (1993-07-01), Winter
patent: 5278299 (1994-01-01), Wong et al.
patent: 5422120 (1995-06-01), Kim
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5510261 (1996-04-01), Goochee et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5604202 (1997-02-01), Kessler et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5750373 (1998-05-01), Garrard et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5814482 (1998-09-01), Dubensky, Jr. et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5866692 (1999-02-01), Shitara et al.
patent: 5981568 (1999-11-01), Kunz et al.
patent: 5997867 (1999-12-01), Waldmann et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6548640 (2003-04-01), Winter
patent: 7306793 (2007-12-01), Haddada et al.
patent: 7384632 (2008-06-01), Devaux et al.
patent: 2004/0137513 (2004-07-01), Devaux et al.
patent: 2005/0089521 (2005-04-01), Shelton
patent: 2007/0014786 (2007-01-01), Shelton
patent: 2007/0036794 (2007-02-01), Devaux et al.
patent: 0345242 (1989-02-01), None
patent: 0524968 (1995-06-01), None
patent: 2200651 (1988-08-01), None
patent: WO8704462 (1987-07-01), None
patent: WO9007936 (1990-07-01), None
patent: WO9011092 (1990-10-01), None
patent: WO9100360 (1991-01-01), None
patent: WO9100904 (1991-01-01), None
patent: WO9102805 (1991-03-01), None
patent: WO9114445 (1991-10-01), None
patent: WO9220373 (1992-11-01), None
patent: WO9303769 (1993-03-01), None
patent: WO9310218 (1993-05-01), None
patent: WO9311230 (1993-06-01), None
patent: WO9319191 (1993-09-01), None
patent: WO9325234 (1993-12-01), None
patent: WO9325698 (1993-12-01), None
patent: WO9403622 (1994-02-01), None
patent: WO9404690 (1994-03-01), None
patent: WO9412649 (1994-06-01), None
patent: WO9423697 (1994-10-01), None
patent: WO9428938 (1994-12-01), None
patent: WO9500655 (1995-01-01), None
patent: WO9507994 (1995-03-01), None
patent: WO9511984 (1995-05-01), None
patent: WO9513796 (1995-05-01), None
patent: WO9530763 (1995-11-01), None
patent: WO9617072 (1996-06-01), None
patent: WO9742338 (1997-11-01), None
patent: WO 99/07410 (1999-02-01), None
patent: WO9958572 (1999-11-01), None
patent: WO0053211 (2000-09-01), None
patent: WO0198361 (2001-12-01), None
patent: WO2004058184 (2004-07-01), None
patent: WO 2004058190 (2004-07-01), None
Rudikoff, Giusti, Cook, and Scharff. Single amino acid substitution altering antigen-binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1983.
Mac Callum, Martin, and Thornton. Antibody-antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Schlom, and Kashmiri. Grafting of abbreviated complementarity determining regions containing specificity determining residues essential for ligand contact to engineer a less immunogenic humanzied monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Vajdos, Adams, Breece, Presta, De Vos, Sidhu. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320, pp. 415-428.
Holm, Jafari, and Sundstrom. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Chen, Wiesmann, Fuh, Li, Christinger, Mc Kay, De Vos, and Lowman. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
Wu, Nie, Huse, and Watkins. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecular Biology, 1999. vol. 294, pp. 151-162.
Nielson, et al., “Affinity Maturation by Chain Shuffling and Site Directed Mutagenesis,” Antibody Engineering (Springer Lab Manuals), May 1, 2001, ISBN: 3-540-41354-5, pp. 515-539.
Takkinen, et al., “Affinity and Specificity Maturation by CDR Walking,” Antibody Engineering (Springer Lab Manuals), May 1, 2001, ISBN: 3-540-41354-5, pp. 540-545.
Urfer, et al., J.Biol. Chem., vol. 273(10), pp. 5829-5840 (1998).
Barbacid, J. Neurobiol., vol. 25, pp. 1386-1403 (1994).
Barbacid, Ann. New York Aced. Sci., vol. 766, pp. 442-458 (1995).
Rydén, et al., J. Biol. Chem., vol. 271(10), pp. 5623-5627 (1996).
Belliveau, et al., J. Cell. Biol., vol. 136, pp. 375-388 (1997).
Farinas, et al., Neuron, vol. 21, pp. 325-334 (1998).
Chaudhry, et al., Muscle and Nerve, vol. 23, pp. 189-192 (2000).
Haase, et al., J. Neurol. Sci., vol. 160, pp. S97-S105 (1998).
Helgren, et al., J. Neurosci., vol. 17(1), pp. 372-382 (1997).
Armour, et al., Eur. J. Immunol., vol. 29, pp. 2613-2624 (1999).
McCafferty, et al., Nature, vol. 348, pp. 552-554 (1990).
Vaughan, et al., Nature Biotech., vol. 14, pp. 309-314 (1996).
Sheets, et al., PNAS (USA), vol. 95, pp. 6157-6162 (1998).
Hoogenboom, et al., J. Mol. Biol., vol. 227, pp. 381-388 (1991).
Marks, et al., J. Mol. Biol. vol. 222, pp. 581-597 (1991).
Boerner, et al., J. Immunol., vol. 147(1), p. 86-95 (1991).
Al-Lazikani, et al., J. Mol. Biol., vol. 273, pp. 927-948 (1997).
Shelton, et al., J. Neurosci., vol. 15(1), pp. 477-497 (1995).
Ravetch, et al., Ann. Rev. Immunol., vol. 9, pp. 457-492 (1991).
Capel, et al., Immunomethods, vol. 4, pp. 25-34 (1994).
de Haas, et al., J. Lab. Clin. Med., vol. 126, pp. 330-341 (1995).
Guyer, et al., J. Immunol., vol. 117, pp. 587-593 (1976).
Gazzano-Santoro, et al., J. Immunol. Methods, vol. 202, pp. 163-171 (1997).
Clynes, et al., PNAS (USA), vol. 95, pp. 652-656 (1998).
Sadick, et al., Exp. Cell. Res., vol. 234, pp. 354-361 (1997).
Bird, et al., Science, vol. 242, pp. 423-426 (1988).
Holliger, et al., PNAS (USA), vol. 90, pp. 6444-6448 (1993).
Poljak, et al., Structure, vol. 2, pp. 1121-1123 (1994).
Suresh, et al., Methods in Enzymology, vol. 121, pp. 210-228 (1986).
Millstein, et al., Nature, vol. 305, pp. 537-539 (1983).
Jefferis, et al., Chem. Immunol., vol. 65, pp. 111-128 (1997).
Wright, et al., TibTECH, vol. 15, pp. 26-32 (1997).
Boyd, et al., Mol. Immunol., vol. 32(17), pp. 1311-1318 (1995).
Wittwer, et al., Biochemistry, vol. 29, pp. 4175-4180 (1990).
Wyss, et al., Current Opin. Biotech., vol. 7, pp. 409-416 (1996).
Uma{umlaut over (n)}a, et al., Nature Biotech., vol. 17, pp. 176-180 (1999).
Hsu, et al., J. Biol. Chem., vol. 272; pp. 9062-9070 (1997).
Barbas, et al., PNAS (USA), vol. 91, pp. 3809-3813 (1994).
Schier, et al.,
Gussow Anne M.
Pfizer Patent Dept.
Rinat Neuroscience Corp.
LandOfFree
Agonist anti-trkC antibodies and methods using same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agonist anti-trkC antibodies and methods using same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agonist anti-trkC antibodies and methods using same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2694881